The Technical Analyst
Select Language :

Leap Therapeutics Inc [LPTX]

Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Leap Therapeutics Inc is listed at the NASDAQ Exchange

-4.81% $2.28

Last updated: 21 Jan 2022 @ 12:44 pm


FUNDAMENTALS
MarketCap: 200.92 mill
EPS: -0.476
P/E: 0.000
Earnings Date: Mar 10, 2022
SharesOutstanding: 88.32 mill
Avg Daily Volume: 1.902 mill
RATING 2022-01-20
B+
Buy
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Neutral
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/203/204/201/212/213/21
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/an/an/an/a
Ebit
Asset
Debt
DISCOUNTED CASH FLOW VALUE
$2.96
(29.91%) $0.680
Date: 2022-01-21

Insider Trading

Date Person Action Amount type
2021-09-24 Beigene, Ltd. Buy 2 543 800 Common Stock
2021-09-24 Perceptive Advisors Llc Buy 3 508 771 Warrants (right to buy)
2021-09-08 Bertagnolli Monica Buy 65 000 Stock Option (Right to Buy)
2021-09-08 Bertagnolli Monica Buy 16 150 Stock Option (Right to Buy)
2021-05-26 Mirabelli Christopher Buy 30 000 Stock Option (Right to Buy)
INSIDER POWER
38.22
Last 100 transactions
Buy: 17 277 901 | Sell: 5 961 887

Forecast: 14:23 - $2.26

Live Trading Signals (every 1 min)

Forecast 1: 12:53 - $2.27
Forecast 2: 13:43 - $2.27
Forecast 3: 14:23 - $2.26
SCORE
-10.00
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $2.28 (-4.81% )
Volume 1.913 mill
Avg. Vol. 1.902 mill
% of Avg. Vol 100.60 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Leap Therapeutics Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Leap Therapeutics Inc

RSI

Intraday RSI14 chart for Leap Therapeutics Inc

Last 10 Buy & Sell Signals For LPTX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

Date Signal @ Closed %
Jan 21 - 17:25sell$2.28N/AActive
The Live Chart for Leap Therapeutics Inc
Profile picture for
            Leap Therapeutics Inc

LPTX

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company is headquartered in Cambridge, Massachusetts and currently employs 23 full-time employees. The Company’s programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body’s immune system to identify and attack cancer. DKN-01 and TRX518 are its clinical stage programs. DKN-01 is a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). GITR is a receptor found on the surface of a wide range of immune cells.

Last 10 Buy Signals
Date Signal @
RVMDJan 21 - 17:34$23.29
SECOJan 21 - 17:34$0.341
RDUSJan 21 - 17:34$6.59
PRAXJan 21 - 17:34$15.29
ORGOJan 21 - 17:34$7.60
MVISJan 21 - 17:34$3.18
MYSZJan 21 - 17:34$0.409
NDAQJan 21 - 17:34$179.46
MRSNJan 21 - 17:34$5.27
MREOJan 21 - 17:34$1.195

Stock Peers

Company Price Change
LPTX2.28-4.81%
ARAV2.27-0.44%
ASRT2.09-5.03%
CDTX0.844-1.94%
COCP0.516-6.51%
CYCN1.2604.13%
MBRX1.560-7.15%
NERV0.840-0.37%
TCON2.17-3.56%
VERO1.500-3.85%
VYNT1.220-5.43%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.